{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T18:31:17Z","timestamp":1788546677038,"version":"build-2803163510"},"reference-count":23,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2023,3,9]],"date-time":"2023-03-09T00:00:00Z","timestamp":1678320000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Mirati Therapeutics, Inc"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,4,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Adagrasib (MRTX849) is a KRASG12C inhibitor with favorable properties, including long half-life (23 h), dose-dependent pharmacokinetics, and central nervous system (CNS) penetration. As of September 1, 2022, a total of 853 patients with KRASG12C-mutated solid tumors, including patients with CNS metastases, had received adagrasib (monotherapy or in combination). Adagrasib-related treatment-related adverse events (TRAEs) are generally mild to moderate in severity, start early in treatment, resolve quickly with appropriate intervention, and result in a low rate of treatment discontinuation. Common TRAEs seen in clinical trials included gastrointestinal-related toxicities (diarrhea, nausea, and vomiting); hepatic toxicities (increased alanine aminotransferase\/aspartate aminotransferase) and fatigue, which can be managed through dose modifications, dietary modifications, concomitant medications (such as anti-diarrheals and anti-emetics\/anti-nauseants) and the monitoring of liver enzymes and electrolytes. To manage common TRAEs effectively, it is imperative that clinicians are informed, and patients are fully counseled on management recommendations at treatment initiation. In this review, we provide practical guidance on the management of adagrasib TRAEs and discuss some best practices for patient and caregiver counseling to facilitate optimal outcomes for patients. Safety and tolerability data from the phase II cohort of the KRYSTAL-1 study will be reviewed and presented with practical management recommendations based on our experience as clinical investigators.<\/jats:p>","DOI":"10.1093\/oncolo\/oyad051","type":"journal-article","created":{"date-parts":[[2023,3,9]],"date-time":"2023-03-09T14:49:31Z","timestamp":1678373371000},"page":"287-296","source":"Crossref","is-referenced-by-count":21,"title":["Practical Guidance for the Management of Adverse Events in Patients with KRASG12C-Mutated Non-Small Cell Lung Cancer Receiving Adagrasib"],"prefix":"10.1093","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7886-6187","authenticated-orcid":false,"given":"Jun","family":"Zhang","sequence":"first","affiliation":[{"name":"Division of Medical Oncology, Department of Internal Medicine, Department of Cancer Biology, University of Kansas Medical Center , Kansas City, KS , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Johnson","sequence":"additional","affiliation":[{"name":"Sarah Cannon Research Institute Tennessee Oncology , Nashville, TN , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minal","family":"Barve","sequence":"additional","affiliation":[{"name":"Mary Crowley Cancer Research , Dallas, TX , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lyudmila","family":"Bazhenova","sequence":"additional","affiliation":[{"name":"UC San Diego Moores Cancer Center , La Jolla, CA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marybeth","family":"McCarthy","sequence":"additional","affiliation":[{"name":"Thoracic Oncology Clinical Trials, Henry Ford Cancer Institute , Detroit, MI , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rowena","family":"Schwartz","sequence":"additional","affiliation":[{"name":"University of Cincinnati , Cincinnati, OH , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elise","family":"Horvath-Walsh","sequence":"additional","affiliation":[{"name":"Mirati Therapeutics, Inc. , San Diego, CA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Velastegui","sequence":"additional","affiliation":[{"name":"Mirati Therapeutics, Inc. , San Diego, CA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunlin","family":"Qian","sequence":"additional","affiliation":[{"name":"Mirati Therapeutics, Inc. , San Diego, CA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1303-0447","authenticated-orcid":false,"given":"Alexander","family":"Spira","sequence":"additional","affiliation":[{"name":"Virginia Cancer Specialists , Fairfax, VA , USA"},{"name":"NEXT Oncology Virginia, US Oncology Research , The Woodlands, TX , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,3,9]]},"reference":[{"key":"2023041314291419500_","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1038\/s41392-021-00780-4","article-title":"KRAS mutation: from undruggable to druggable in cancer.","volume":"6","author":"Huang","year":"2021","journal-title":"Transduct Target Ther."},{"key":"2023041314291419500_","doi-asserted-by":"crossref","first-page":"e120858","DOI":"10.1172\/jci.insight.120858","article-title":"Personalized therapy for lung cancer: striking a moving target","volume":"3","author":"Pakkala","year":"2018","journal-title":"JCI Insight"},{"key":"2023041314291419500_","doi-asserted-by":"crossref","first-page":"8535","DOI":"10.1038\/srep08535","article-title":"Comparative analysis of KRAS codon 12, 13, 18, 61, and 117 mutations using human MCF10A isogenic cell lines","volume":"5","author":"Stolze","year":"2015","journal-title":"Sci Rep."},{"key":"2023041314291419500_","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1158\/2159-8290.CD-19-1167","article-title":"The KRASG12C inhibitor MRTX849 provides insight toward therapeutic susceptibility of kRAS-mutant cancers in mouse models and patients.","volume":"10","author":"Hallin","year":"2020","journal-title":"Cancer Discov."},{"key":"2023041314291419500_","doi-asserted-by":"crossref","first-page":"6679","DOI":"10.1021\/acs.jmedchem.9b02052","article-title":"Identification of the clinical development candidate MRTX849, a covalent KRASG12C inhibitor for the treatment of cancer","volume":"63","author":"Fell","year":"2020","journal-title":"J Med Chem."},{"key":"2023041314291419500_","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1200\/JCO.21.02752","article-title":"First-in-human phase I\/Ib dose-finding study of adagrasib (MRTX849) in patients with advanced KRASG12C solid tumors (KRYSTAL-1)","volume":"40","author":"Ou","year":"2022","journal-title":"J Clin Oncol."},{"key":"2023041314291419500_","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1056\/NEJMoa2204619","article-title":"Adagrasib in non-small-cell lung cancer harboring a KRASG12C mutation","volume":"387","author":"J\u00e4nne","year":"2022","journal-title":"N Engl J Med."},{"key":"2023041314291419500_","doi-asserted-by":"crossref","article-title":"KRYSTAL-1: updated activity and safety of adagrasib (MRTX849) in patients (pts) with unresectable or metastatic pancreatic cancer (PDAC) and other gastrointestinal (GI) tumors harboring a KRASG12C mutation.","author":"Bekaii-Saab","DOI":"10.1200\/JCO.2022.40.4_suppl.519"},{"key":"2023041314291419500_","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/S0959-8049(20)31077-7","article-title":"KRYSTAL-1: activity and safety of adagrasib (MRTX849) in patients with colorectal cancer (CRC) and other solid tumors harboring a KRASG12C mutation","volume":"138","author":"Johnson","year":"2020","journal-title":"Eur J Cancer."},{"key":"2023041314291419500_","doi-asserted-by":"crossref","first-page":"S1294","DOI":"10.1016\/j.annonc.2021.08.2093","article-title":"LBA6 - KRYSTAL-1: adagrasib (MRTX849) as monotherapy of in combination with cetuximab in patients with colorectal cancer harboring a KRASG12C mutation","volume":"32","author":"Weiss","year":"2021","journal-title":"Ann Oncol."},{"key":"2023041314291419500_","doi-asserted-by":"crossref","first-page":"3318","DOI":"10.1158\/1078-0432.CCR-22-0383","article-title":"Activity of adagrasib (MRTX849) in brain metastases: preclinical models and clinical data from patients with KRASG12C-mutant non-small cell lung cancer","volume":"28","author":"Sabari","year":"2022","journal-title":"Clin Cancer Res."},{"key":"2023041314291419500_","doi-asserted-by":"crossref","article-title":"Activity of adagrasib (MRTX849) in patients with KRASG12C -mutated NSCLC and active, untreated CNS metastases in the KRYSTAL-1 trial.","author":"Sabari","DOI":"10.1200\/JCO.2022.40.17_suppl.LBA9009"},{"key":"2023041314291419500_","doi-asserted-by":"crossref","article-title":"1133P - Additional \u00adpractice-informing adverse event patterns and management in the KRYSTAL-1 phase II study of adagrasib (MRTX849) in patients with KRASG12C-mutated NSCLC","author":"Zhang","DOI":"10.1016\/j.annonc.2022.07.1257"},{"key":"2023041314291419500_","author":"National Comprehensive Cancer Network"},{"key":"2023041314291419500_","first-page":"CD006788","article-title":"Pharmacological treatments for fatigue associated with palliative care","volume":"2015","author":"M\u00fccke","year":"2015","journal-title":"Cochrane Database Syst Rev."},{"key":"2023041314291419500_","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1002\/cpt.2489","article-title":"Time to rethink the current paradigm for assessing kidney function in drug development and beyond","volume":"112","author":"Sharma","year":"2022","journal-title":"Clin Pharmacol Ther."},{"key":"2023041314291419500_","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1136\/heart.89.11.1363","article-title":"Drug induced QT prolongation and torsades de pointes","volume":"89","author":"Yap","year":"2003","journal-title":"Heart."},{"key":"2023041314291419500_","doi-asserted-by":"crossref","first-page":"S188","DOI":"10.1097\/CCM.0b013e3181de112a","article-title":"Drug-induced arrhythmias.","volume":"38","author":"Barnes","year":"2010","journal-title":"Crit Care Med."},{"key":"2023041314291419500_","doi-asserted-by":"crossref","first-page":"995","DOI":"10.2147\/PPA.S341966","article-title":"Adherence to oral targeted anti-lung cancer therapy: a qualitative interview study.","volume":"16","author":"Zhou","year":"2022","journal-title":"Patient Prefer Adher."},{"key":"2023041314291419500_","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.1016\/j.amjmed.2005.12.021","article-title":"Approaches to patient education: emphasizing the long-term value of compliance and persistence","volume":"119","author":"Gold","year":"2006","journal-title":"Am J Med."},{"key":"2023041314291419500_","author":"Food and Drug Administration"},{"key":"2023041314291419500_","author":"Food and Drug Administration"},{"key":"2023041314291419500_","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1056\/NEJMoa2212419","article-title":"Adagrasib with or without cetuximab in colorectal cancer with mutated KRAS G12C.","volume":"388","author":"Yaeger","year":"2022","journal-title":"New Engl J Med."}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/28\/4\/287\/49880494\/oyad051.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/28\/4\/287\/49880494\/oyad051.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,7]],"date-time":"2023-12-07T01:16:33Z","timestamp":1701911793000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/28\/4\/287\/7074098"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,9]]},"references-count":23,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2023,3,9]]},"published-print":{"date-parts":[[2023,4,6]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyad051","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,4,1]]},"published":{"date-parts":[[2023,3,9]]}}}